Gérard Delbeke

Indigo Diabetes Announces First Participant Enrolled in the SHINE Clinical Trial

Retrieved on: 
Thursday, September 29, 2022
Ljubljana University Medical Centre, Enzyme, Light, Safety, Trial of the century, SHINE, Biomarker, Blood, Glucose, NSAIDS, Diabetes, Ketone, Dexcom, Clinical trial, Exercise, CEO, Internet, UZA, Silicon, CGM, CMM, Gérard Delbeke, G6, Skin, Absorption, GLOW, Pharmaceutical industry, Medical device, Medical imaging, Indigo

BELGIUM Ghent, September 29, 2022 Indigo Diabetes N.V. (Indigo or the Company), a pioneering developer of medical solutions using nanophotonics, today announces the enrollment of the first participant in Belgium in the SHINE clinical trial, which is designed to evaluate the longer-term stability of Indigos continuous multi-metabolite (CMM) device.

Key Points: 
  • BELGIUM Ghent, September 29, 2022 Indigo Diabetes N.V. (Indigo or the Company), a pioneering developer of medical solutions using nanophotonics, today announces the enrollment of the first participant in Belgium in the SHINE clinical trial, which is designed to evaluate the longer-term stability of Indigos continuous multi-metabolite (CMM) device.
  • Indigo has recently submitted a paper on the data from its successfully concluded GLOW trial, the first-in-human clinical study of Indigos CMM sensor, to a peer-reviewed journal for publication.
  • Professor Christophe De Block, Principal Investigator of the SHINE trial at Antwerp University Hospital commented: Continuous monitoring of glucose levels is key in managing diabetes to prevent devastatingacute and long-term complications.
  • It is a privilege to lead the SHINE clinical trial to evaluate the safety and performance of this ground-breaking novel technology.

Indigo Diabetes Announces First Participant Enrolled in the SHINE Clinical Trial

Retrieved on: 
Thursday, September 29, 2022
Ljubljana University Medical Centre, Enzyme, Light, Safety, Trial of the century, SHINE, Biomarker, Blood, Glucose, NSAIDS, Diabetes, Ketone, Dexcom, Clinical trial, Exercise, CEO, Internet, UZA, Silicon, CGM, CMM, Gérard Delbeke, G6, Skin, Absorption, GLOW, Pharmaceutical industry, Medical device, Medical imaging, Indigo

BELGIUM Ghent, September 29, 2022 Indigo Diabetes N.V. (Indigo or the Company), a pioneering developer of medical solutions using nanophotonics, today announces the enrollment of the first participant in Belgium in the SHINE clinical trial, which is designed to evaluate the longer-term stability of Indigos continuous multi-metabolite (CMM) device.

Key Points: 
  • BELGIUM Ghent, September 29, 2022 Indigo Diabetes N.V. (Indigo or the Company), a pioneering developer of medical solutions using nanophotonics, today announces the enrollment of the first participant in Belgium in the SHINE clinical trial, which is designed to evaluate the longer-term stability of Indigos continuous multi-metabolite (CMM) device.
  • Indigo has recently submitted a paper on the data from its successfully concluded GLOW trial, the first-in-human clinical study of Indigos CMM sensor, to a peer-reviewed journal for publication.
  • Professor Christophe De Block, Principal Investigator of the SHINE trial at Antwerp University Hospital commented: Continuous monitoring of glucose levels is key in managing diabetes to prevent devastatingacute and long-term complications.
  • It is a privilege to lead the SHINE clinical trial to evaluate the safety and performance of this ground-breaking novel technology.

Indigo Diabetes Business Update

Retrieved on: 
Tuesday, December 21, 2021
University of Ljubljana, EU, Coronavirus Scientific Advisory Board (Turkey), Metabolism, University, Skin, CGM, Philip Morris, Life, Trial of the century, Jindal Centre for Social Innovation & Entrepreneurship, Board, Lists of diseases, Light, Diabetes, Absorption, Diamond, CEO, Gérard Delbeke, Glucose meter, SAB, Daniel, Silicon, Safety, Flanders, Medical school, Research, New Year, GLOW, Hannover Medical School, CMM, Innovation, School, Department, Board of directors, Metabolic disorder, Enzyme, University of Antwerp, Endocrinology, York University, Internet, Kinesiology, Glucose, Medical device, Pharmaceutical industry, Indigo

BELGIUM Ghent, December 21, 2021 Indigo Diabetes N.V. (Indigo or the Company), a pioneering developer of medical solutions using nanophotonics, today provides an update on recent and ongoing business activities.

Key Points: 
  • BELGIUM Ghent, December 21, 2021 Indigo Diabetes N.V. (Indigo or the Company), a pioneering developer of medical solutions using nanophotonics, today provides an update on recent and ongoing business activities.
  • In addition, Indigo appointed seven internationally recognised experts in endocrinology, diabetes and metabolic disease to form its newly created Scientific Advisory Board (SAB).
  • Dr Dana Delbeke, CEO, Inventor and Co-founder of Indigo Diabetes, commented: I am very proud of the significant progress made by our multidisciplinary team at Indigo to develop our CMM sensor in 2021.
  • Indigo Diabetes N.V. (Indigo) is a pioneering developer of medical solutions utilizing nanophotonics.

Indigo Diabetes Business Update

Retrieved on: 
Tuesday, December 21, 2021
University of Ljubljana, EU, Coronavirus Scientific Advisory Board (Turkey), Metabolism, University, Skin, CGM, Philip Morris, Life, Trial of the century, Jindal Centre for Social Innovation & Entrepreneurship, Board, Lists of diseases, Light, Diabetes, Absorption, Diamond, CEO, Gérard Delbeke, Glucose meter, SAB, Daniel, Silicon, Safety, Flanders, Medical school, Research, New Year, GLOW, Hannover Medical School, CMM, Innovation, School, Department, Board of directors, Metabolic disorder, Enzyme, University of Antwerp, Endocrinology, York University, Internet, Kinesiology, Glucose, Medical device, Pharmaceutical industry, Indigo

BELGIUM Ghent, December 21, 2021 Indigo Diabetes N.V. (Indigo or the Company), a pioneering developer of medical solutions using nanophotonics, today provides an update on recent and ongoing business activities.

Key Points: 
  • BELGIUM Ghent, December 21, 2021 Indigo Diabetes N.V. (Indigo or the Company), a pioneering developer of medical solutions using nanophotonics, today provides an update on recent and ongoing business activities.
  • In addition, Indigo appointed seven internationally recognised experts in endocrinology, diabetes and metabolic disease to form its newly created Scientific Advisory Board (SAB).
  • Dr Dana Delbeke, CEO, Inventor and Co-founder of Indigo Diabetes, commented: I am very proud of the significant progress made by our multidisciplinary team at Indigo to develop our CMM sensor in 2021.
  • Indigo Diabetes N.V. (Indigo) is a pioneering developer of medical solutions utilizing nanophotonics.